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Objective:  There  are  several  types  of  orofacial  neuropathic  pain  and some  of  these  types  are  often  refrac-
tory  to treatment.  Gabapentin  is an  oral  antiepileptic  agent  with  a proven  analgesic  effect  in  various
traumatic  neuropathic  pain  syndromes.  We  retrospectively  examined  the  analgesic  effect  of  gabapentin
on  non-dental  and  non-traumatic  orofacial  neuropathic  pain.
Subjects and  methods:  This  study  included  12 patients.  All  patients  showed  an  excessive  response  to
noxious  (hyperalgesia)  and/or  innocuous  (allodynia)  stimuli  in  the  affected  region.  Gabapentin  therapy
was  initiated  with  a dosage  of 200–600  mg/day.  Pain  intensity  was  assessed  using  a modiﬁed  numerical
rating  scale  (m-NRS)  (0, no pain;  10,  pain  equal  to that  experienced  on  the  day  gabapentin  therapy  was
initiated).  In  addition,  the  side  effects  were  also  recorded.
Results: All  the  patients  had  received  medications  for their  pain  prior  to  referral,  but the  drugs  failed  to
provide  adequate  relief  from  their  neuropathic  pain.  The  m-NRS  scores  for all  patients  started  decreasing
within  7  days  after  internal  use was  initiated.  The  average  time  taken  for  the  m-NRS  score  to  decrease  to
half  was  3.3  (1.7)  days.  Side  effects  were  observed  in 2  patients.
Conclusion: We  concluded  that  gabapentin  therapy  is efﬁcacious  for the  treatment  of orofacial  neuropathic
pain  in  selected  patients.
 Japan© 2011
. Introduction
Neuropathic pain has been deﬁned by the International Asso-
iation for the Study of Pain as pain was initiated or caused by a
rimary lesion or dysfunction in the nervous system [1] There are
everal types of orofacial neuropathic pain, for example, stabbing
ain, shooting pain, and continuous dull pain; some of these types
re often refractory to treatment.
Gabapentin  is an oral antiepileptic agent with an unknown
echanism of action and has already been used in some coun-
ries for neuropathic pain [2–4]. Gabapentin was approved as an
ntiepileptic agent in Japan in September 2006. Because gabapentin
s an anticonvulsant with a proven analgesic effect in various trau-
atic neuropathic pain syndromes, we used this drug for treating
on-dental and non-traumatic orofacial neuropathic pain, exclud-
ng psychophysiologic disorders. We  retrospectively evaluated the
fﬁcacy and side effects of gabapentin therapy for orofacial neuro-
athic pain.∗ Corresponding author. Tel.: +81 92 801 1011x3537; fax: +81 92 801 1044.
E-mail  address: miichan@minf.med.fukuoka-u.ac.jp (M.  Seto).
348-8643/$ – see front matter ©  2011 Japanese Stomatological Society. Published by Els
oi:10.1016/S1348-8643(11)00002-4ese Stomatological Society. Published by Elsevier Ltd. All rights reserved.
2. Patients and methods
This  study included 12 patients who  had been referred to
Fukuoka University Hospital for orofacial pain in a wide range of
areas. We  could not diagnose idiopathic cranial neuralgias because
the pain site was different from the nerve controlled site or had a
long duration; therefore, we  decided to aim for cases considered as
having peripheral neuropathic pain. All the patients had failed to
obtain relief from pain with previous pharmacologic interventions.
Gabapentin therapy was  initiated with a dosage of
200–600 mg/day. For those patients who  were unsteady while
walking or used a stick, 200 mg/day was initiated before sleeping
and the dosage was increased while conﬁrming that there was
no change in their walking condition as a result of the drug
administration. For those patients who were relatively healthy
with no walking problem, 600 mg/day (3 times after each meal)
was administered in accordance with the administration method
for epilepsy treatment. The dosage was increased every 7th day in
order to relieve pain. Pain intensity was  assessed using a modiﬁed
numerical rating scale (m-NRS) (m-NRS scores: 0, no pain; 10,
pain equal to that experienced on the day gabapentin therapy
was initiated). The period during which the analgesic effect of
gabapentin became apparent corresponded to the period when
the m-NRS score started to decrease and we thus, determined the
evier Ltd. All rights reserved.
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ime at which the m-NRS score reduced to half the initial score. In
ddition, the side effects were also recorded.
. Results
This study included 12 patients (women, 8; men, 4; age,
2.6 ± 14.7 years). Of these patients, 4 had cervicofacial pain; 3,
andibular gingival pain; 3, glossopharyngeal nerve pain; and 2,
ongue margin pain.
Neuropathic  pain presented as continuous stabbing pain in 5
atients, shooting pain in 9 patients, and continuous burning pain
n 4 patients (some patients experienced more than one type of
ain). All patients showed an excessive response to noxious (hyper-
lgesia) and/or innocuous (allodynia) stimuli in the affected region
Table 1). All the patients had received medications [nonsteroidal
nti-inﬂammatory drugs (NSAIDs) and/or carbamazepine] for their
ain prior to referral, but the drugs failed to provide adequate relief
rom their neuropathic symptoms (Table 2).
The m-NRS scores for all patients started decreasing within 7
ays after internal use was initiated. The average time taken for
he m-NRS score to decrease to half was 3.3 ± 1.7 days (Table 2).
The follow-up period ranged from 5 to 19 months, during which
he median pain level decreased to 0/10; however, 2 patients with-
rew from gabapentin therapy because of side effects. One of the
ide effects was skin symptoms (slight redness of the brow) and
he other one was dizziness. One patient started to experience skin
ymptoms after 13 days of gabapentin administration, and this dis-
ppeared in 2 days after the discontinuation of the drug use. In
nother case, a patient complained of dizziness, 4 days after the
tart of the gabapentin administration, and had a remission of the
ymptom immediately after the cessation. However, severe side
ffects were not seen in any of our patients.
. Discussion
The term “neuropathic pain” is used for pain syndromes for
hich the sustaining mechanisms are presumed to be related to
berrant somatosensory processes in the peripheral nervous sys-
em, central nervous system, or in both [5]. Neuropathic pain
rises as a direct consequence of a lesion or disease affecting the
omatosensory system. Neuropathic pain cannot be explained by
 single disease process or a single speciﬁc location of damage.
ommon types of pain include burning, stabbing, numbness, and
hooting. Almost all of our patients had pain on peripheral nerves
f the face and neck. And then, we diagnosed the patients as having
neuropathic pain.”
Gabapentin  was designed as a structural analog of -
minobutyric acid (GABA) but does not act on any known receptors
n the brain, including GABA receptors [6]. Unlike other antiepilep-
ic drugs, the receptor activity proﬁle of gabapentin has not yet
een determined, which supports the hypothesis that it has a
ovel mechanism of action [2]. Several studies have reported that
abapentin is effective in the treatment of postradical neck pain
yndrome, postherpetic neuralgia, and postsurgical facial pain [3,4].
e examined the analgesic effect of gabapentin on non-dental and
on-traumatic orofacial trigeminal neuropathic pain.
Tricyclic antidepressants and anticonvulsant drugs are often the
rst-line drugs to be selected for alleviating orofacial trigeminal
europathic pain (ﬁrst-line pharmacological treatment). Anticon-
ulsant drugs such as carbamazepine remain the best option for
reating trigeminal neuralgia; glossopharyngeal neuralgia is also
till treated using these drugs. Although anticonvulsant drugs are
ffective in reducing pain in several neuropathic pain disorders,
reatment may  be compromised and outweighed by their side
ffects. Current clinical treatments for neuropathic pain include Ta
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Table  2
Previous treatment for the orofacial pain and results of gabapentin therapy.
Case number Previous treatment Effective daily
gabapentin dose
(mg/day)
Days  for m-NRS <5
(days)
Follow-up  time
(months)
Side  effect
1 NSAIDs 800 3 7
2 Amitriptyline  1200 4 6
3  Carbamazepine 300 2 16
4  NSAIDs, carbamazepine 200 4 5
5  NSAIDs 400 2 13
6 200 2 Stop Dizziness
7 NSAIDs,  carbamazepine 600 5 Stop Slight redness of the brow
8 SNRI  1200 4 9
9  Antianxiety drugs 900 3 9
10  NSAIDs, carbamazepine 700 2 7
11  Carbamazepine, SSRI 1200 5 19
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w12  Carbamazepine 200 2
-NRS, modiﬁed numerical rating scale. Scores: 0, no pain; 10, pain equal to that e
mitriptyline, a tricyclic antidepressant that has mixed pharma-
ology and is clinically reported to impair cognitive performance,
nd gabapentin, a compound that selectively interacts with -
 -1 calcium-channel subunits. The rapid entry of calcium into
ells through activation of voltage-gated calcium channels directly
ffects membrane potential and contributes to electrical excitabil-
ty. At presynaptic nerve terminals, calcium entry is the initial
rigger mediating the release of neurotransmitters via the calcium-
ependent fusion of synaptic vesicles and involves interactions
ith the soluble N-ethylmaleimide-sensitive factor attachment
rotein receptor complex of synaptic release proteins. Physiologi-
al factors or drugs that affect either presynaptic calcium channel
ctivity have consequences on synaptic transmission, including
ediating pain signaling. The N-type calcium channel exhibits a
umber of characteristics that make it a target for therapeutic inter-
ention concerning chronic and neuropathic pain conditions [7]. Its
xact mechanism of action is unknown, but gabapentin is thought
o bind to the calcium channel in the central nervous system.
The  common side effects of tricyclic antidepressants are mostly
ue to their anticholinergic activity and include dry mouth, drowsi-
ess, nausea, dizziness, urinary retention, arrhythmias, and hepatic
oxicity. Gabapentin is emerging as a ﬁrst-line treatment for neu-
opathic pain in patients with a history of cardiovascular disorders,
laucoma, and urine retention [8,9]. Carbamazepine is not rec-
mmended for neuropathic pain other than trigeminal neuralgia
ecause of the side effects. Often, the required multidrug ther-
py results in more side effects and drug interactions [10]. Drug
nteractions should be considered in the case of patients who reg-
larly use medicines for underlying disease. Antiepileptic drugs
ave a favorable safety proﬁle with minimal concerns regard-
ng drug interactions and show no interference with hepatic
nzymes.
The most common side effects of antiepileptic agents are dizzi-
ess and somnolence. The side effects were observed in 2 patients
13.3%) in our study. One of the side effects was dizziness and
he other was slight redness of the brow. Because the effects
ppeared with a comparatively low starting dose, the appear-
nce of side effects could be controlled, and in other reports as
ell [4].
[18
nced on the day gabapentin therapy was initiated.
All our patients experienced adequate relief from their severe
pain during gabapentin therapy, and the analgesic effect of
gabapentin was obtained as early as 3.3 days after initiation of
therapy in this study. Because there were only few side effects
related to gabapentin therapy and an analgesic effect was obtained
at an earlier stage than with tricyclic antidepressants, we think
that gabapentin is more effective than tricyclic antidepressants in
treating orofacial neuropathic pain.
Of our 12 patients, 2 had pain for less than 1 month at the time
of initial evaluation, suggesting that spontaneous recovery rather
than efﬁcacy of gabapentin therapy might have been responsible
for the favorable outcome in these cases. However, this possibility
is unlikely as they experienced recurrence of pain after discontin-
uation of gabapentin therapy.
We  conclude that gabapentin therapy is efﬁcacious for the treat-
ment of orofacial neuropathic pain in selected patients.
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